Needle-free Treatments for Autoimmune Disorders from Switzerland

It’s back to go back to the mainland. This week’s stop is in Hergiswill, a city by one of the many beautiful seas that can be found in Switzerland. There, the young biotech BioLingus is developing needle-free therapies for chronic diseases.

BioLingus Logo

City: Hergiswill, Switzerland

Founded: 2014

Employees: 1-10

Financial data: N/A

Yves Decadt BioLingus CEO

Yves Decadt, CEO

Mission: BioLingus develops non-invasive treatments for autoimmune and inflammatory diseases, such as diabetes, Crohn’s and celiac disease. Its therapies are delivered under the tongue or via the nose instead.

Comment: BioLingus is working on oral vaccines against flu and the tropical disease leishmaniasis, tablets for children with type 1 diabetes and an oral version of AstraZeneca‘s diabetes drug exenatide. Its most ambitious project is an oral therapy for rheumatoid arthritis to compete with AbbVie’s Humira, the top-selling drug, as well as Janssen’s Remicade and Amgen’s Enbrel. Together, they make over €19B ($20B) in sales annually.

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.